Back to Results

Codexis Inc (CDXS)

Featured in High-Beta Stocks

Codexis, Inc. is a healthcare company listed on NASDAQ as common stock. The company develops enzyme-based technology for therapeutics manufacturing, centered on its CodeEvolver platform, which is used to discover, develop, improve, and commercialize novel enzymes. It also works on the ECO Synthesis manufacturing platform, designed to support scaled RNAi therapeutics production through an enzymatic process. Codexis conducts business across North America, Europe, the Middle East, Africa, Asia-Pacific, and China. The company has license agreements with Aldevron LLC and Pfizer Inc. Founded in 2002, Codexis is headquartered in Redwood City, California.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-CDXS
$2.34
5.3% Upside
Fair
$6.58
195.9% Upside
Bargain
Fair
—
—
—
0.0%
July 30, 2026
-6.3x
4.7x
2.6x
200.9 M
208 M
26.6%
80.8%
-4.8
—
69.1%
Send a message
Valuation • Fair Value

Codexis Inc (NASDAQ-CDXS) Fair Value by Valuation Model

Compare the primary fair value estimate for Codexis Inc (NASDAQ-CDXS) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$2.34

Estimated upside of 5.3% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$2.25

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$1.16

Earnings power value estimate.

Comps Fair Value

$2.62

Comparable-company valuation reference.

Analyst Price Target

$6.58

Analysts imply upside of 195.9%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Codexis Inc (NASDAQ-CDXS) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Codexis Inc (NASDAQ-CDXS)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

78.092 M

Current operating scale indicator.

Revenue Forecast

73.846 M

Forward revenue estimate.

EBITDA

-20.55 M

Current operating profitability reference.

EBITDA Forecast

-21.1 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Codexis Inc (NASDAQ-CDXS) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Codexis Inc (NASDAQ-CDXS)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-4.00

No elevated caution signal from this screen.

Altman Z-Score

-4.8

Lower score that deserves closer risk review.

FCF / Net Income

69.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Codexis Inc (NASDAQ-CDXS). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Codexis Inc (NASDAQ-CDXS)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 30, 2026

Days to Earnings

9

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Codexis Inc (NASDAQ-CDXS), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Codexis Inc (NASDAQ-CDXS) Stock Forecast & Technical Outlook

Review Codexis Inc (NASDAQ-CDXS) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Codexis Inc (NASDAQ-CDXS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Buy

The 1-hour technical read for Codexis Inc (NASDAQ-CDXS) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Codexis Inc (NASDAQ-CDXS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Codexis Inc (NASDAQ-CDXS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for Codexis Inc (NASDAQ-CDXS) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Codexis Inc (NASDAQ-CDXS)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Codexis Inc (NASDAQ-CDXS) has a Buy consensus, with 4 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 4
Hold 2
Sell 0
FAQ • Fast Investor Answers

Codexis Inc (NASDAQ-CDXS) Stock FAQ

Quick answers about Codexis Inc (NASDAQ-CDXS) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$2.34
Estimated upside 5.3%
Valuation Rating
Undervalued
Estimated upside of 5.3%
Analyst Target
$6.58
Implied upside 195.9%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Codexis Inc (NASDAQ-CDXS) is $2.34. This implies an estimated upside of 5.3% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 5.3% versus the current market price.

The available analyst price target for Codexis Inc (NASDAQ-CDXS) is $6.58. The analyst target implies estimated upside of 195.9%.

The current financial health read for Codexis Inc (NASDAQ-CDXS) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Codexis Inc (NASDAQ-CDXS) is July 30, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Codexis Inc (NASDAQ-CDXS) is -6.3x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Codexis Inc is 200.9 M.

The current enterprise value listed for Codexis Inc is 208 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Codexis Inc is NASDAQ-CDXS, and the stock is listed on NASDAQ.

Codexis Inc (NASDAQ-CDXS) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Codexis Inc is 26.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Codexis Inc is 80.8%. Free float helps investors understand how much of the share base is available for public trading.

Similar Life Sciences Tools & Services Stocks on NASDAQ View more

Illumina Inc (ILMN) Illumina Inc (ILMN)
Medpace Holdings Inc (MEDP) Medpace Holdings Inc (MEDP)
ICON PLC (ICLR) ICON PLC (ICLR)
Bio-Techne Corp (TECH) Bio-Techne Corp (TECH)
Tempus AI Inc (TEM) Tempus AI Inc (TEM)
Bruker Corporation (BRKR) Bruker Corporation (BRKR)
Repligen Corporation (RGEN) Repligen Corporation (RGEN)
10X Genomics Inc (TXG) 10X Genomics Inc (TXG)
Sotera Health Co (SHC) Sotera Health Co (SHC)
Adaptive Biotechnologies Corp (ADPT) Adaptive Biotechnologies Corp (ADPT)
Maravai Lifesciences Holdings Inc (MRVI) Maravai Lifesciences Holdings Inc (MRVI)
Abcellera Biologics Inc (ABCL) Abcellera Biologics Inc (ABCL)
Fortrea Holdings Inc (FTRE) Fortrea Holdings Inc (FTRE)
BioLife Solutions Inc (BLFS) BioLife Solutions Inc (BLFS)
Personalis Inc (PSNL) Personalis Inc (PSNL)
Azenta Inc (AZTA) Azenta Inc (AZTA)
Cryoport Inc (CYRX) Cryoport Inc (CYRX)
Evotec SE ADR (EVO) Evotec SE ADR (EVO)
Cytek Biosciences Inc (CTKB) Cytek Biosciences Inc (CTKB)
Mesa Laboratories Inc (MLAB) Mesa Laboratories Inc (MLAB)
Pacific Biosciences of California (PACB) Pacific Biosciences of California (PACB)
Standard Biotools Inc (LAB) Standard Biotools Inc (LAB)
OmniAb Inc (OABI) OmniAb Inc (OABI)
Alpha Teknova Inc (TKNO) Alpha Teknova Inc (TKNO)